Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

High blood pressure alone can damage kidneys, study finds
High blood pressure alone can damage kidneys, study finds
A new study from the Medical University of Vienna shows that high blood pressure on its own—without other health problems like diabetes—can cause early damage to the kidneys.
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics
Supernus Pharmaceuticals has acquired Sage Therapeutics, strengthening its neuropsychiatry product portfolio.
Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump
Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump
Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.
African countries plan shift to healthcare funding autonomy amid aid cuts
African countries plan shift to healthcare funding autonomy amid aid cuts
The WHO's director-general says leaders want self-reliance, with tobacco and alcohol tax rises on the cards to boost domestic revenue.
Scotiabank raises Apellis Pharmaceuticals stock price target on FDA approval
Scotiabank raises Apellis Pharmaceuticals stock price target on FDA approval
Scotiabank raised its price target on Apellis Pharmaceuticals to $22.00 from $20.00 on Wednesday, while maintaining a Sector Perform rating following FDA approval of Empaveli (Pegcetacoplan).
MIRA Pharmaceuticals Reports
MIRA Pharmaceuticals Reports
MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
Ivonescimab Displays Preclinical Feasibility in Frontline ccRCC
Ivonescimab Displays Preclinical Feasibility in Frontline ccRCC
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
MetrioPharm gains orphan drug status from EMA for MP1032
MetrioPharm gains orphan drug status from EMA for MP1032
MetrioPharm’s lead compound, MP1032, has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for treating Duchenne muscular dystrophy (DMD) in chi...
Roche’s Alzheimer’s therapy shows continued benefit
Roche’s Alzheimer’s therapy shows continued benefit
Roche’s Alzheimer’s therapy shows continued benefit
FDA Knew Drugmaker Had Poor Record. It Waited Four Years to Inspect One Factory
FDA Knew Drugmaker Had Poor Record. It Waited Four Years to Inspect One Factory
FDA Knew Drugmaker Had Poor Record. It Waited Four Years to Inspect One Factory
GSK's $12 Billion Hengrui Pharma Partnership
GSK's $12 Billion Hengrui Pharma Partnership
GSK's $12 Billion Hengrui Pharma Partnership: A Catalyst for Pipeline Growth and Therapeutic Leadership Beyond 2031
MAIA Biotechnology Reports FDA's
MAIA Biotechnology Reports FDA's
MAIA Biotechnology Reports FDA's Fast Track Designation For Ateganosine
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand